Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The Biosimilars Market Report Is Available Now!
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

Recent Posts

  • Biosimilar Clinical Trial Costs in Terms of Expense and Time October 13, 2020
  • The FDA’s View of the COVID-19 Pandemic’s Effect on Biosimilar Development October 9, 2020
  • US Biosimilar Market Will Soon Catch up to the EU October 2, 2020
  • Four-Letter Suffixes May Be FDA’s Own Brand of Misleading Information on Biosimilars September 17, 2020
  • A Profile on Lesser-Known Player in the Biosimilar Space: NeuClone September 10, 2020
  • Who Are the Key Aflibercept Biosimilar Players to Watch? August 31, 2020
  • Biosimilar Bytes August 27, 2020
  • Employers, Biosimilars, and Pharmaceutical Benefits: Something’s Gotta Give August 20, 2020
  • The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics August 14, 2020
  • A Profile of a Lesser-Known Player in the Biosimilar Space: Alvotech August 7, 2020

Recent Comments

Nancy Globus on Four-Letter Suffixes May Be FD…
EVI on Who Are the Key Aflibercept Bi…
Prof. Dr. Arnold G.… on Biosimilar Switching: The Evid…
STEVEN J. MILLER on Prescription Abandonment and t…
Nesta on Bevacizumab ASP Pricing now Dr…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Biosimilar Approval Status
  • The Evolution of the Biosimilars Market
  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
  • Ruxience
  • Biosimilar Clinical Trial Costs in Terms of Expense and Time
  • Amgen Settles With Alexion on Soliris Biosimilar, Dropping Litigation and Getting a Release Date
  • Pfizer Launches Ruxience, Announces Pricing for Upcoming Trazimera
  • Abrilada
  • A Profile of a Lesser-Known Player in the Biosimilar Space: Alvotech
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2015-2020 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.